What do we know about IDH1/2 mutations so far, and how do we use it?

Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma

(2015) Kasthuri Kannan et al.   Oncotarget

How Molecular Testing Can Help (and Hurt) in the Workup of Gliomas

(2013) Kenneth Clark et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

A Novel COLD-PCR/FMCA Assay Enhances the Detection of Low-abundance IDH1 Mutations in Gliomas

(2013) Brendan Pang et al.   DIAGNOSTIC MOLECULAR PATHOLOGY

Interlaboratory comparison of IDH mutation detection

(2013) Martin J. van den Bent et al.   JOURNAL OF NEURO-ONCOLOGY

IDH/MGMT-driven molecular classification of low-grade glioma is a strong predictor for long-term survival

(2013) S. Leu et al.   NEURO-ONCOLOGY

Inherited variant on chromosome 11q23 increases susceptibility to IDH-mutated but not IDH-normal gliomas regardless of grade or histology

(2013) T. Rice et al.   NEURO-ONCOLOGY

Low rate of R132H IDH1 mutation in infratentorial and spinal cord grade II and III diffuse gliomas

(2012) Benjamin Ellezam et al.   ACTA NEUROPATHOLOGICA

CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas

(2012) Felix Sahm et al.   ACTA NEUROPATHOLOGICA

Enzymatic assay for quantitative analysis of (d)-2-hydroxyglutarate

(2012) Jörg Balss et al.   ACTA NEUROPATHOLOGICA

Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations

(2012) Xiao-Yang Liu et al.   ACTA NEUROPATHOLOGICA

K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas

(2012) Dong-Anh Khuong-Quang et al.   ACTA NEUROPATHOLOGICA

Relationship between Tumor Enhancement, Edema,IDH1Mutational Status,MGMTPromoter Methylation, and Survival in Glioblastoma

(2012) J.A. Carrillo et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

Nuclear Exclusion of TET1 Is Associated with Loss of 5-Hydroxymethylcytosine in IDH1 Wild-Type Gliomas

(2012) Tim Müller et al.   AMERICAN JOURNAL OF PATHOLOGY

Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response

(2012) A. T. Fathi et al.   BLOOD

Prognostic impact of the isocitrate dehydrogenase 1 single-nucleotide polymorphism rs11554137 in malignant gliomas

(2012) Xiao-Wei Wang et al.   CANCER

Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma

(2012) Dominik Sturm et al.   CANCER CELL

Disruption of Wild-Type IDH1 Suppresses D-2-Hydroxyglutarate Production in IDH1-Mutated Gliomas

(2012) G. Jin et al.   CANCER RESEARCH

IDH Mutation and Neuroglial Developmental Features Define Clinically Distinct Subclasses of Lower Grade Diffuse Astrocytic Glioma

(2012) D. Gorovets et al.   CLINICAL CANCER RESEARCH

Clinical Implications of Molecular Neuropathology and Biomarkers for Malignant Glioma

(2012) Ghazaleh Tabatabai et al.   Current Neurology and Neuroscience Reports

D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function

(2012) M. Sasaki et al.   GENES & DEVELOPMENT

A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation

(2012) C. G. Duncan et al.   GENOME RESEARCH

Prognostic value of Ki67 index in anaplastic oligodendroglial tumours - a translational study of the European Organization for Research and Treatment of Cancer Brain Tumor Group

(2012) Matthias Preusser et al.   HISTOPATHOLOGY

Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma

(2012) Benjamin R. Kipp et al.   HUMAN PATHOLOGY

IDH1/2 mutation is a prognostic marker for survival and predicts response to chemotherapy for grade II gliomas concomitantly treated with radiation therapy

(2012) YOSHIKO OKITA et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

The Potential for Isocitrate Dehydrogenase Mutations to Produce 2-Hydroxyglutarate Depends on Allele Specificity and Subcellular Compartmentalization

(2012) Patrick S. Ward et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Cancer-associated Isocitrate Dehydrogenase Mutations Inactivate NADPH-dependent Reductive Carboxylation

(2012) Roberta Leonardi et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951

(2012) Martin J. van den Bent et al.   JOURNAL OF CLINICAL ONCOLOGY

Expression of R132H Mutational IDH1 in Human U87 Glioblastoma Cells Affects the SREBP1a Pathway and Induces Cellular Proliferation

(2012) Jian Zhu et al.   JOURNAL OF MOLECULAR NEUROSCIENCE

No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas

(2012) Rezvan Ahmadi et al.   JOURNAL OF NEURO-ONCOLOGY

1P19Q loss but not IDH1 mutations influences WHO grade II gliomas spontaneous growth

(2012) Catherine Gozé et al.   JOURNAL OF NEURO-ONCOLOGY

Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors

(2012) Shingo Takano et al.   JOURNAL OF NEURO-ONCOLOGY

The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas

(2012) T. A. Juratli et al.   JOURNAL OF NEURO-ONCOLOGY

IDH mutations as an early and consistent marker in low-grade astrocytomas WHO grade II and their consecutive secondary high-grade gliomas

(2012) Tareq A. Juratli et al.   JOURNAL OF NEURO-ONCOLOGY

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial

(2012) Annika Malmström et al.   LANCET ONCOLOGY

Diagnostic implications of IDH1-R132H and OLIG2 expression patterns in rare and challenging glioblastoma variants

(2012) Nancy M Joseph et al.   MODERN PATHOLOGY

IDH mutation impairs histone demethylation and results in a block to cell differentiation

(2012) Chao Lu et al.   NATURE

Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation

(2012) Peppi Koivunen et al.   NATURE

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

(2012) Sevin Turcan et al.   NATURE

Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma

(2012) Jeremy Schwartzentruber et al.   NATURE

IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics

(2012) Masato Sasaki et al.   NATURE

A low-frequency variant at 8q24.21 is strongly associated with risk of oligodendroglial tumors and astrocytomas with IDH1 or IDH2 mutation

(2012) Robert B Jenkins et al.   NATURE GENETICS

Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas

(2012) Gang Wu et al.   NATURE GENETICS

2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas

(2012) Changho Choi et al.   NATURE MEDICINE

Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation

(2012) J. Lazovic et al.   NEURO-ONCOLOGY

Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation

(2012) Sichen Li et al.   NEURO-ONCOLOGY

Detection of IDH1 mutation in the plasma of patients with glioma

(2012) B. Boisselier et al.   NEUROLOGY

Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia

(2012) Jay P. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Reverse TCA cycle flux through isocitrate dehydrogenases 1 and 2 is required for lipogenesis in hypoxic melanoma cells

(2012) Fabian V. Filipp et al.   Pigment Cell & Melanoma Research

TET2 Mutations Are Associated with Specific 5-Methylcytosine and 5-Hydroxymethylcytosine Profiles in Patients with Chronic Myelomonocytic Leukemia

(2012) Cristina Pérez et al.   PLoS One

Clonal Analysis in Recurrent Astrocytic, Oligoastrocytic and Oligodendroglial Tumors Implicates IDH1- Mutation as Common Tumor Initiating Event

(2012) Ulrike Lass et al.   PLoS One

Detection of 2-Hydroxyglutarate in IDH-Mutated Glioma Patients by In Vivo Spectral-Editing and 2D Correlation Magnetic Resonance Spectroscopy

(2012) O. C. Andronesi et al.   Science Translational Medicine

Magnetic Resonance of 2-Hydroxyglutarate in IDH1-Mutated Low-Grade Gliomas

(2012) A. Elkhaled et al.   Science Translational Medicine

IDH1/2 mutations in WHO grade II astrocytomas associated with localization and seizure as the initial symptom

(2012) Florian Stockhammer et al.   SEIZURE-EUROPEAN JOURNAL OF EPILEPSY

Base-Pair Resolution DNA Methylation Sequencing Reveals Profoundly Divergent Epigenetic Landscapes in Acute Myeloid Leukemia

(2012) Altuna Akalin et al.   PLoS Genetics

Loss of ATRX, Genome Instability, and an Altered DNA Damage Response Are Hallmarks of the Alternative Lengthening of Telomeres Pathway

(2012) Courtney A. Lovejoy et al.   PLoS Genetics

Adult grade II diffuse astrocytomas are genetically distinct from and more aggressive than their paediatric counterparts

(2011) David T. W. Jones et al.   ACTA NEUROPATHOLOGICA

Whole-exome sequencing detects somatic mutations of IDH1 in metaphyseal chondromatosis with D-2-hydroxyglutaric aciduria (MC-HGA)

(2011) Lisenka E.L.M. Vissers et al.   AMERICAN JOURNAL OF MEDICAL GENETICS PART A

Mutant IDH1 Confers an in Vivo Growth in a Melanoma Cell Line with BRAF Mutation

(2011) Tatsuhiro Shibata et al.   AMERICAN JOURNAL OF PATHOLOGY

Absence of IDH1-R132H mutation predicts rapid progression of nonenhancing diffuse glioma in older adults

(2011) Adriana Olar et al.   Annals of Diagnostic Pathology

IDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo

(2011) Linda B. C. Bralten et al.   ANNALS OF NEUROLOGY

NOA-05 phase 2 trial of procarbazine and lomustine therapy in gliomatosis cerebri

(2011) Martin Glas et al.   ANNALS OF NEUROLOGY

Addressing Diffuse Glioma as a Systemic Brain Disease With Single-Cell Analysis

(2011) David Capper   ARCHIVES OF NEUROLOGY

A Tale of Two Subunits: How the Neomorphic R132H IDH1 Mutation Enhances Production of αHG

(2011) Beth Pietrak et al.   BIOCHEMISTRY

IDH1mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival

(2011) Niklas Thon et al.   CANCER

Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases

(2011) Wei Xu et al.   CANCER CELL

Monoallelic Expression Determines Oncogenic Progression and Outcome in Benign and Malignant Brain Tumors

(2011) E. J. Walker et al.   CANCER RESEARCH

Evolved Tumor Suppression: Why Are We So Good at Not Getting Cancer?

(2011) J. DeGregori   CANCER RESEARCH

IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma

(2011) Qi SongTao et al.   CANCER SCIENCE

The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases

(2011) Rasheduzzaman Chowdhury et al.   EMBO REPORTS

Protective role of cytosolic NADP+-dependent isocitrate dehydrogenase, IDH1, in ischemic pre-conditioned kidney in mice

(2011) Jinu Kim et al.   FREE RADICAL RESEARCH

2-Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size

(2011) David Capper et al.   INTERNATIONAL JOURNAL OF CANCER

MGMT CpG island is invariably methylated in adult astrocytic and oligodendroglial tumors with IDH1 or IDH2 mutations

(2011) Shani Mulholland et al.   INTERNATIONAL JOURNAL OF CANCER

Evidence for Sequenced Molecular Evolution of IDH1 Mutant Glioblastoma From a Distinct Cell of Origin

(2011) Albert Lai et al.   JOURNAL OF CLINICAL ONCOLOGY

TET2 promoter methylation in low-grade diffuse gliomas lacking IDH1/2 mutations

(2011) Y.-H. Kim et al.   JOURNAL OF CLINICAL PATHOLOGY

Differential Activity of NADPH-Producing Dehydrogenases Renders Rodents Unsuitable Models to Study IDH1R132 Mutation Effects in Human Glioblastoma

(2011) Nadia A. Atai et al.   JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY

The sodium-dependent di- and tricarboxylate transporter, NaCT, is not responsible for the uptake of D-, L-2-hydroxyglutarate and 3-hydroxyglutarate into neurons

(2011) Katja Brauburger et al.   JOURNAL OF INHERITED METABOLIC DISEASE

Prognostic stratification of gliomatosis cerebri by IDH1R132H and INA expression

(2011) Virginie Desestret et al.   JOURNAL OF NEURO-ONCOLOGY

IDH mutation status impact on in vivo hypoxia biomarkers expression: new insights from a clinical, nuclear imaging and immunohistochemical study in 33 glioma patients

(2011) Philippe Metellus et al.   JOURNAL OF NEURO-ONCOLOGY

Value and Limitations of Immunohistochemistry and Gene Sequencing for Detection of theIDH1-R132HMutation in Diffuse Glioma Biopsy Specimens

(2011) Matthias Preusser et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers

(2011) Stephen Yip et al.   JOURNAL OF PATHOLOGY

IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours

(2011) M Fernanda Amary et al.   JOURNAL OF PATHOLOGY

Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic Study of 277 patients

(2011) M M Patnaik et al.   LEUKEMIA

IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F

(2011) A Tefferi et al.   LEUKEMIA

Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2

(2011) M Fernanda Amary et al.   NATURE GENETICS

An in vivo patient-derived model of endogenous IDH1-mutant glioma

(2011) H. A. Luchman et al.   NEURO-ONCOLOGY

Identification of additional IDH mutations associated with oncometabolite R(−)-2-hydroxyglutarate production

(2011) P S Ward et al.   ONCOGENE

Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping

(2011) D. R. Borger et al.   ONCOLOGIST

2-Hydroxyglutarate Production, but Not Dominant Negative Function, Is Conferred by Glioma-Derived NADP+-Dependent Isocitrate Dehydrogenase Mutations

(2011) Genglin Jin et al.   PLoS One

Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH Mutations in Glioblastoma

(2011) Daniel Krell et al.   PLoS One

The CDKN2A G500 Allele Is More Frequent in GBM Patients with No Defined Telomere Maintenance Mechanism Tumors and Is Associated with Poorer Survival

(2011) Janice A. Royds et al.   PLoS One

Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome

(2011) Z. J. Reitman et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of  -ketoglutarate to citrate to support cell growth and viability

(2011) D. R. Wise et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mutations in CIC and FUBP1 Contribute to Human Oligodendroglioma

(2011) C. Bettegowda et al.   SCIENCE

Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing

(2010) Jörg Felsberg et al.   ACTA NEUROPATHOLOGICA

The prognostic IDH1 R132 mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma

(2010) Fonnet E. Bleeker et al.   ACTA NEUROPATHOLOGICA

R132H-mutation of isocitrate dehydrogenase-1 is not sufficient for HIF-1α upregulation in adult glioma

(2010) Susan C. Williams et al.   ACTA NEUROPATHOLOGICA

Detection of IDH1 mutations in gliomatosis cerebri, but only in tumors with additional solid component: evidence for molecular subtypes

(2010) Marcel Seiz et al.   ACTA NEUROPATHOLOGICA

Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas

(2010) Christian Hartmann et al.   ACTA NEUROPATHOLOGICA

Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology

(2010) David Capper et al.   ACTA NEUROPATHOLOGICA

Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis

(2010) Philippe Metellus et al.   ACTA NEUROPATHOLOGICA

Molecular Classification of Low-Grade Diffuse Gliomas

(2010) Young-Ho Kim et al.   AMERICAN JOURNAL OF PATHOLOGY

IDH1R132 mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain

(2010) Giselle Y. Lopez et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value

(2010) S. Abbas et al.   BLOOD

The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status

(2010) C. L. Green et al.   BLOOD

The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate

(2010) Patrick S. Ward et al.   CANCER CELL

Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma

(2010) Houtan Noushmehr et al.   CANCER CELL

Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation

(2010) Maria E. Figueroa et al.   CANCER CELL

Inhibition of Glutaminase Preferentially Slows Growth of Glioma Cells with Mutant IDH1

(2010) M. J. Seltzer et al.   CANCER RESEARCH

Molecular mechanisms of “off-on switch” of activities of human IDH1 by tumor-associated mutation R132H

(2010) Bei Yang et al.   CELL RESEARCH

IDH1 mutations are common in malignant gliomas arising in adolescents: a report from the Children’s Oncology Group

(2010) Ian F. Pollack et al.   CHILDS NERVOUS SYSTEM

Diagnostic and prognostic markers in gliomas

(2010) François Ducray et al.   CURRENT OPINION IN ONCOLOGY

Increased levels of 2-hydroxyglutarate in AML patients with IDH1-R132H and IDH2-R140Q mutations

(2010) Leopold Sellner et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

An overview of L-2-hydroxyglutarate dehydrogenase gene (L2HGDH) variants: a genotype-phenotype study

(2010) Marjan E. Steenweg et al.   HUMAN MUTATION

Segregation of non-p.R132H mutations inIDH1in distinct molecular subtypes of glioma

(2010) Lonneke A.M. Gravendeel et al.   HUMAN MUTATION

Molecular signatures classify astrocytic gliomas byIDH1mutation status

(2010) Grischa Toedt et al.   INTERNATIONAL JOURNAL OF CANCER

Impact of IDH1 R132 Mutations and an IDH1 Single Nucleotide Polymorphism in Cytogenetically Normal Acute Myeloid Leukemia: SNP rs11554137 Is an Adverse Prognostic Factor

(2010) Katharina Wagner et al.   JOURNAL OF CLINICAL ONCOLOGY

IDH1andIDH2Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

(2010) Guido Marcucci et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations

(2010) Stefan Gross et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Detection of IDH1 and IDH2 Mutations by Fluorescence Melting Curve Analysis as a Diagnostic Tool for Brain Biopsies

(2010) Craig Horbinski et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Presence of Alternative Lengthening of Telomeres Mechanism in Patients With Glioblastoma Identifies a Less Aggressive Tumor Type With Longer Survival

(2010) Kerrie L. McDonald et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

DNA Methylation, Isocitrate Dehydrogenase Mutation, and Survival in Glioma

(2010) Brock C. Christensen et al.   JNCI-Journal of the National Cancer Institute

The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia

(2010) W-C Chou et al.   LEUKEMIA

Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis

(2010) J. Laffaire et al.   NEURO-ONCOLOGY

First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response

(2010) W. Taal et al.   NEURO-ONCOLOGY

IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas

(2010) C. Houillier et al.   NEUROLOGY

All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2

(2010) M. Labussiere et al.   NEUROLOGY

Mutational analysis of D2HGDH and L2HGDH in brain tumours without IDH1 or IDH2 mutations

(2010) S. Brehmer et al.   NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY

Scientific correspondence

(2010) S. Pusch et al.   NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY

Cancer-associated IDH mutations: biomarker and therapeutic opportunities

(2010) K E Yen et al.   ONCOGENE

IDH2 Mutations in Patients with D-2-Hydroxyglutaric Aciduria

(2010) M. Kranendijk et al.   SCIENCE

Selective acquisition of IDH1 R132C mutations in astrocytomas associated with Li-Fraumeni syndrome

(2009) Takuya Watanabe et al.   ACTA NEUROPATHOLOGICA

Monoclonal antibody specific for IDH1 R132H mutation

(2009) David Capper et al.   ACTA NEUROPATHOLOGICA

Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma

(2009) Andrey Korshunov et al.   ACTA NEUROPATHOLOGICA

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas

(2009) Christian Hartmann et al.   ACTA NEUROPATHOLOGICA

Mutant IDH1-specific immunohistochemistry distinguishes diffuse astrocytoma from astrocytosis

(2009) Sandra Camelo-Piragua et al.   ACTA NEUROPATHOLOGICA

IDH1 Mutations Are Early Events in the Development of Astrocytomas and Oligodendrogliomas

(2009) Takuya Watanabe et al.   AMERICAN JOURNAL OF PATHOLOGY

PCR- and Restriction Endonuclease-Based Detection ofIDH1Mutations

(2009) Jochen Meyer et al.   BRAIN PATHOLOGY

Characterization of R132H Mutation-specific IDH1 Antibody Binding in Brain Tumors

(2009) David Capper et al.   BRAIN PATHOLOGY

Intrinsic Gene Expression Profiles of Gliomas Are a Better Predictor of Survival than Histology

(2009) L. A.M. Gravendeel et al.   CANCER RESEARCH

IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas

(2009) S. Nobusawa et al.   CLINICAL CANCER RESEARCH

Silencing of cytosolic NADP+-dependent isocitrate dehydrogenase by small interfering RNA enhances the sensitivity of HeLa cells toward staurosporine

(2009) Su-Min Lee et al.   FREE RADICAL RESEARCH

IDH1mutations at residue p.R132 (IDH1R132) occur frequently in high-grade gliomas but not in other solid tumors

(2009) Fonnet E. Bleeker et al.   HUMAN MUTATION

Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers

(2009) Mi Ran Kang et al.   INTERNATIONAL JOURNAL OF CANCER

Isocitrate Dehydrogenase Mutations Are Rare in Pheochromocytomas and Paragangliomas

(2009) José Gaal et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network

(2009) Michael Weller et al.   JOURNAL OF CLINICAL ONCOLOGY

Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas

(2009) Marc Sanson et al.   JOURNAL OF CLINICAL ONCOLOGY

NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide

(2009) Wolfgang Wick et al.   JOURNAL OF CLINICAL ONCOLOGY

Diagnostic Use ofIDH1/2Mutation Analysis in Routine Clinical Testing of Formalin-Fixed, Paraffin-Embedded Glioma Tissues

(2009) Craig Horbinski et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

L-2-Hydroxyglutaric Aciduria and Brain Tumors

(2009) Nalan Yazici et al.   JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY

Association of reactive oxygen species levels and radioresistance in cancer stem cells

(2009) Maximilian Diehn et al.   NATURE

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

(2009) Lenny Dang et al.   NATURE

IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas

(2009) Koichi Ichimura et al.   NEURO-ONCOLOGY

IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide

(2009) H. J. Dubbink et al.   NEUROLOGY

IDH1andIDH2Mutations in Gliomas

(2009) Hai Yan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1 

(2009) S. Zhao et al.   SCIENCE

Analysis of the IDH1 codon 132 mutation in brain tumors

(2008) Jörg Balss et al.   ACTA NEUROPATHOLOGICA

Hydroxyglutaric aciduria and malignant brain tumor: a case report and literature review

(2008) Mahdi Aghili et al.   JOURNAL OF NEURO-ONCOLOGY

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

(2008) D. W. Parsons et al.   SCIENCE